In addition, specific immune checkpoint inhibitors are being explored as new immunotherapeutic strategies for osteosarcoma, such as CTLA-4, LAG3, TIGIT, and PD-1/L1 (Wang S.-D. Here, TIGIT is linked to osteosarcoma.